About: http://data.cimple.eu/news-article/f78e0ec3985279072e7580e3cd023ad77c19d6ba49e78ca37d34b3b3

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/f78e0ec3985279072e7580e3cd023ad77c19d6ba49e78ca37d34b3b3 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	South Africa said Sunday it would suspend the start of its Covid-19 vaccinations after a study showed the AstraZeneca jab failed to prevent mild and moderate cases of the virus variant that has appeared in the country. Africa's hardest-hit nation was due to start its campaign in the coming days with a million doses of the vaccine developed by AstraZeneca and Oxford. "It's a temporary issue that we have to hold on AstraZeneca until we figure out these issues," Health Minister Zweli Mkhize told reporters during a virtual press conference. The University of Witwatersrand, Johannesburg, which conducted the trial, said in a statement on Sunday that the AstraZeneca vaccine "provides minimal protection against mild-moderate Covid-19 infection" from the South African variant. But in a full paper due to be published on Monday, AstraZeneca said that none of the 2,000 participants developed serious symptoms. That could mean it will still have an effect on severe illness, although not yet enough data is available to make a definitive judgement. Lagging behind in the global vaccination race, South Africa received its first delivery of a million doses on Monday. An additional 500,000 doses are expected this month. All are AstraZeneca vaccines produced by the Serum Institute of India and some 1.2 million health workers are to be first in line for the shots. "In the next four weeks, we will have the J&J and Pfizer," said Mkhize, referring to vaccines made by Johnson & Johnson and Pfizer/BioNTech. Discussions with other vaccine producers are also ongoing, particularly Moderna and the makers of the Russian Sputnik V jab. Mkhize recently announced having reserved 20 million Pfizer/BioNTech doses. The 1.5 million AstraZeneca vaccines obtained by South Africa, which will expire in April, will be kept until scientists give clear indications on their use, he said. "The second generation of the vaccine to fight all variants will take longer to produce," said Salim Abdool Karim, epidemiologist and co-chair of the scientific committee at the South African health ministry. South Africa plans to vaccinate at least 67 percent of its population by the end of the year, or around 40 million people. The country has recorded more than 1.5 million infections and over 46,000 deaths from the virus. cld/sba/mjs/gd
schema:headline	S.Africa suspends vaccination launch over AstraZeneca study
schema:mentions	Epidemiology Johannesburg Johnson & Johnson Sputnik 1 Jab Ebola virus disease University of Oxford Africa AstraZeneca South Africa Russian language Pfizer India Vaccine Coronavirus disease 2019 Study South Africa Salim Abdool Karim University of the Witwatersrand Zweli Mkhize
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-02-07 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	73 (xsd:integer)
http://data.cimple...tology#hasEmotion	anger

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software